C4 Therapeutics
reported initial Phase 1 first-in-human results for cemsidomide (CFT7455), a novel MonoDAC IKZF1/3 degrader, in patients with non-Hodgkin's lymphoma.
- Country
- United States
- Ticker
- CCCC
MonoDAC degrader (cemsidomide)
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| PROTACs (targeted protein degradation) | therapeutics-platforms | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.